Externalize costs without breaking the data value chain

Sponsored by: idbs

Focused on:

  • Research
  • Development
  • Data
  • Value

Date: 17 September


Time: 3PM London/10AM New York

Externalizing discovery screening processes can help with focusing on adding value in-house but it's important to preserve the efficiency and integrity of your data value chain

Join Andy Vines of IDBS and Justin Gazard of Pfizer Inc. as they explore successful approaches to externalization in the drug discovery space. In this session, Andy will take a closer look at the issues around making sure that data generated externally can be easily shared, incorporated back into in-house-systems and that its integrity and transparency leads to fully reproducible results. Justin will be sharing his experience of making collaboration work at Pfizer Inc., and together, both speakers will examine models of collaboration, highlighting best practice for collaboration in life sciences.

Modern R&D (research and development) has brought new players to the scene and challenged old relationships. We’re seeing that externalization and a growing reliance on CROs (Contract Research Organizations) for discovery research upstream of the preclinical and clinical areas has become the norm. But risks lurk. If externalization isn’t properly executed, its benefits can be negated by extended decision cycle times among other serious issues. Efficiency and also trust underpin the success of collaboration. Transparent and reliable infrastructure solutions are key to achieving a positive outcome for all parties.

This is because the USD1.6 trillion global R&D sector is dealing with the challenges of managing the immense amount of data generated by modern drug discovery techniques as well as having to find ways to mitigate costs. Whether it's from the point of view of an organization looking to outsource certain stages of the discovery life cycle, or specialist research service partners, or even academia; today's trends in R&D present challenges as well as opportunities for defining innovative, collaborative partnerships.

Attend our webinar to find out more about how data value can be preserved across externalized, collaborative ways of working. Learn how collaboration and outsourcing can help your organization focus on the value you're looking for without suffering the downsides.

Presented by

Andy Vines,

Product Manager, Screening Solutions, IDBS

With an academic background in pharmacology and biochemistry, Andy Vines is currently the Product Manager responsible for IDBS' screening solutions, including the ActivityBase Suite, ActivityMart and XLfit.

Before joining IDBS in 2008, Andy had already gained extensive user experience of ActivityBase, having used it in his previous R&D-centric roles at GlaxoSmithKline (GSK). During an industry career spanning 20 years, Andy was instrumental in driving forward a number of research programs in oncology and cardiovascular therapeutic areas, primarily in research biology and screening functions covering target ID, hit ID, lead optimization and candidate selection.

His industry expertise and experience of discovery screening place him in an excellent position to advise R&D specialists on how IDBS can help them overcome the many challenges facing a fast-evolving scientific domain.

Justin Gazard,

Pharmacology Data Manager, Pfizer Inc.

Justin Gazard is currently a Pharmacology Data Manager in Research Business Technology at Pfizer Inc. In his role as Technical Implementation Lead for ActivityBase at Pfizer, he is key to strategic implementation of ActivityBase templates and workflows. Justin has been key in defining the strategy for the migration of users across global Research Units and Support Lines from an existing in-house plate-based pharmacology application to the ActivityBase XE Suite. He has played an integral role in the development and implementation of the process to handle outsourced HTS and primary pharmacology data analysis at Pfizer.

Over the last 14 years at Pfizer, Justin has held several roles in Research and Business Technology. He started as a bench scientist for the High Throughput Screening group supporting global early discovery programs. After transitioning to Business Technology in 2008, Justin has brought his deep business knowledge and technical expertise to provide support to biologists across the organization. As the global lead of the Pfizer Pharmacology Data Workflow Council, he drives strategies for managing the generation, capture and visualization of primary pharmacology data generated by an increasingly global network of providers.

Justin holds Master's degrees in Computer Science and Biology from Rensselaer Polytechnic Institute and Brown University.

Key Learning Objectives

  • Approaching externalization – understanding your options
  • Making externalization a reality – getting the infrastructure right
  • Successful externalization – don’t compromise on the efficiency of your data value chain
  • Externalize costs, internalize value – achieving results that matter


  • Screening
  • Research and Discovery
  • IT Managers
  • R&D IT Managers
  • CRO Managers